

Biocept, UC collaborate on predicting disease recurrence in solid tumors

July 24, 2018 | News

Clinical studies with Biocept's Target Selector to evaluate the use of circulating tumor cells in disease assessment, surveillance and monitoring



Singapore - Biocept, a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with a variety of solid tumors. These studies will use Biocept's Target Selector liquid biopsy assays to detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) and compare results with findings from CT or PET scans.

The first study is designed to determine the feasibility of using liquid biopsy to predict disease recurrence in patients with Stage II or III cancer at high risk for recurrence. The second study will evaluate the feasibility of using liquid biopsy to predict response to therapy in patients with metastatic solid tumors. The studies are designed to evaluate Biocept's CTC and ctDNA assays in multiple cancer types, but will focus primarily on CTC biomarkers in patients diagnosed with breast, lung, and colon cancer.

"Despite recent advances in chemotherapy and radiation, risk for post-resection disease recurrence in patients with stage II or stage III solid tumors remains unacceptably high," said Razelle Kurzrock, M.D., Center for Personalized Cancer Therapy and Clinical Trials Office director, Moores Cancer at UC San Diego Health. "The current standard of care to assess disease recurrence is CT imaging, which may only detect recurrence after significant organ damage has occurred. Detecting disease recurrence in these patients with a blood sample may enable more rapid and comprehensive treatment options."